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Nucleoside analogues having a new N,O-containing
tricycle in place of the ribose unit have been prepared by a
diastereoselective cyclocondensation of tris
(hydroxymethyl)aminomethane and dialdehydes obtained
from ribofuranosyl nucleosides by periodate oxidationQ3 .
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Tricyclanos: conformationally constrained
nucleoside analogues with a new heterotricycle
obtained from a D-ribofuranose unit†
MátéQ2 Kicsák,a Attila Mándi, b Szabolcs Varga,a Mihály Herczeg,a Gyula Batta,b
Attila Bényei,c Anikó Borbás *a and Pál Herczegh*a
A novel type of nucleoside analogue in which the sugar part is replaced by a new tricycle, 3,7,10-trioxa-
11-azatricyclo[5.3.1.05,11]undecane has been prepared by substrate-controlled asymmetric synthesis.
1,5-Dialdehydes obtained from properly protected or unprotected uridine, ribothymidine, cytidine, inosine,
adenosine and guanosine by metaperiodate oxidation reacted readily with tris(hydroxymethyl)aminomethane
to provide the corresponding tricyclic derivatives with three new stereogenic centers. Through a double
cyclisation cascade process the tricyclic compounds were obtained in good to high yields, with very high
diastereoselectivity. Formation of one stereoisomer, out of the eight possible, was observed in all cases. The
absolute configuration of the new stereotriad-containing tricyclic systems was aided by conventional NMR
experiments followed by chemical shift calculations using an X-ray crystal structure as reference that was in
good agreement with H–H distances obtained from a new ROESY NMR method. The synthesis was compa-
tible with silyl, trityl and dimethoxytrityl protecting groups. A new reagent mixture containing ZnCl2, Et3SiH
and hexafluoroisopropanol was developed for detritylation of the acid-sensitive tricyclano nucleosides.
Introduction
Nucleoside analogues are able to interfere with the replication
of viruses or with the proliferation of cancer cells by compet-
ing with their natural counterparts. Therefore, chemically
modified nucleosides and nucleotides have attracted consider-
able attention and numerous therapeutically important deriva-
tives have been developed over the past few decades.1–3
Azanucleosides are nucleoside analogues in which the fura-
nose unit has been replaced by a nitrogen-containing ring
including pyrrolidine, piperidine, morpholine, etc. Some aza-
nucleosides are in advanced clinical trials as anticancer
drugs, and others have promising antimalarial, antitrypanoso-
mal and antibacterial properties.4
In the 1990s, Summerton devised and began developing
morpholinos, an important group of azanucleosides having
the morpholine ring in the place of ribose moieties.5 The mor-
pholino monomers can be prepared from simple ribonucleo-
sides by periodate oxidation and a subsequent reductive amin-
ation (Scheme 1a). In these compounds the morpholine ring is
connected to the heterocyclic base recognition moieties of
RNA (adenine, cytosine, uracil and guanine). Oligonucleotide
analogues were prepared from these morpholino derivatives by
coupling the morpholine nitrogen to the phosphoramidite
moiety derived from the primary hydroxyl of another
monomer.6 The phosphorodiamidate connected morpholino
oligomers (PMOs) inhibit the translation of target mRNA by
steric blocking and they are resistant to enzymatic degra-
dation. PMOs proved to be effective antivirals against RNA
viruses.7 They also exhibited antibacterial and anticancer
activities as well as inhibited in-stent restenosis after the
Scheme 1 Synthesis of (a) morpholinos and (b) proposed synthesis of
morpholine-containing tricyclanos.
†Electronic supplementary information (ESI) available: Experimental details,
characterization of all reported compounds, DFT and computational data. CCDC
1571164. For ESI and crystallographic data in CIF or other electronic format see
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implantation of coronary stents and proved to be promising
therapeutic agents in the treatment of Duchenne muscular
dystrophy.8,9 Modified oligonucleotides containing a single
morpholino unit also show potent gene-silencing activity and
prolonged action time.10
The 2′-amino-locked nucleosides, bearing a –CH2–NH-
bridge between the C2′ and C4′ atoms, also represent notable
members of the azanucleoside family.11,12 These nucleoside
derivatives are also a kind of bicyclic morpholine analogue
containing a bridged morpholine ring connected to the
nucleobase. The incorporation of amino-locked nucleosides
and other conformationally restricted bi-, tri- or tetracyclic
monomers into oligonucleotides has been a widely used
approach to produce nucleic acid analogues with increased
duplex stability and high enzymatic stability.13–16 Given the
potential of morpholinos and other azanucleosides as drug
leads, the development of new analogues is an important area
in medicinal and synthetic chemistry. Inspired by both the
gene silencing activity and the special structure of morpholi-
nos, we envisioned the synthesis of a novel type of nucleoside
analogue having structure F, in which the ribose unit is sub-
stituted with a morpholine-containing tricyclic ring system
(Scheme 1b). Due to the two primary hydroxyl groups, these
analogues can be coupled to each other and can be incorpor-
ated into DNA or RNA oligonucleotides at any desired position
using standard phosphoramidite chemistry. Moreover, the
rigidity of the tricyclic sugar mimic could endow the synthetic
oligonucleotides with an increased stability against nucleases.
Cyclocondensation of aminoalcohols and monoaldehydes
is a long-known reaction17 which has been used extensively for
the synthesis of bis-oxazolidine bicyclic systems.18 It was
demonstrated for the first time by Broadbent et al.19 that the
condensation of 2-amino-1,3-propanediols and 1,4-diketones
led to the formation of pyrrolidino-bis-oxazolidine tricycles.
However, the reaction required harsh conditions and use of
p-toluenesulfonic acid in refluxing toluene, and only moderate
yields were achieved. Giovenzana et al.20 described that a com-
pletely stereoselective 2 : 2 condensation of glyoxal and tris
(hydroxymethyl)aminomethane (Tris) took place in aqueous
medium without acid catalysis to give a pentacyclic derivative
in high yield. We assumed that under such mild conditions
cyclocondensation between the 1,5-dialdehyde derivative of
nucleosides (B) and Tris (E) could proceed in a stereoselective
manner providing the desired heterotricyclic derivative (F).
Herein, we present the synthesis and structural determi-
nation of uridine-, ribothymidine-, inosine-, cytidine-, adeno-
sine- and guanosine-derived members of the new nucleoside
family which we suggest to call tricyclanos, by analogy of
Summerton’s morpholinos.
Results and discussion
Synthesis
Our initial experiments were carried out with unprotected
uridine (1), which was oxidized with the metaperiodate form
of an anion exchange resin, and the obtained crude dialde-
hyde was reacted directly with Tris (E) in methanol at room
temperature (Scheme 2). The reaction proceeded cleanly pro-
viding compound 4, one of the eight possible diastereo-
isomers, in 58% yield after column chromatographic purifi-
cation. No other product could be isolated from the reaction
mixture. The moderate yield was caused by the incomplete
conversion of 1 and the difficulty of purification of the product.
In order to discriminate the two primary hydroxyl groups of the
resulting tricyclano and in hope of higher yield, we decided to
block the 5′-hydroxyl function of uridine. Therefore, 1 was regio-
selectively reacted with tert-butyldimethylsilyl (TBDMS) chloride
and the partially blocked 2a21 was subjected to the two-step
transformation including oxidation and condensation with Tris.
To our delight, the cyclocondensation reaction between E and
the dialdehyde22 took place with both high efficacy and stereo-
selectivity to give 3a in 72% yield over two steps, in completely
stereo pure form. Removal of the TBDMS protecting group by
TBAF afforded uracil-tricyclano 4 that was identical to the
compound obtained via dialdehyde without protecting the
5′-hydroxyl group.
Our literature survey revealed that the heterotricyclic ring
system formed by the condensation of the ribose-derived dia-
ldehyde and tris(hydroxymethyl)aminomethane has not been
described until now. The new tricycle has been named as
3,7,10-trioxa-11-azatricyclo[5.3.1.05,11]undecane (Fig. 1). The
absolute configuration of the new stereogenic centers C2, C5
and C8 could be determined by means of X-ray crystallography,
experimental and theoretical NMR methods (vide infra).
As our aim was to prepare nucleoside analogues which can
be incorporated into short oligonucleotides, we tested the
Scheme 2 Synthesis of uracil-tricyclano 4 without protecting groups
and using the 5’-TBDMS, DMTr and Tr protecting groups. Reagents and
conditions: (i) TBDMSCl, imidazole, dry DMF, rt, overnight, 2a: 64%; (ii)
DMTrCl, dry Et3N, dry C5H5N, rt, overnight, 2b: 81%; (iii) TrCl, dry C5H5N,
rt, overnight, 2c: 83%; (iv) IO4
− resin, MeOH, rt, dark, overnight; (v) E, 3 Å
MS, dry MeOH, rt, 3a, 3b: overnight, 3c: 2 days, 3a: 72% (2 steps from
2a), 3b: 76% (2 steps from 2b), 3c: 76% (2 steps from 2c), 4: 58% (2 steps
from 1); (vi) TBAF, dry THF, rt, overnight, 4: 48% (from 3a); (vii) ZnCl2,
(F3C)2CHOH, H3CNO2, Et3SiH, rt, 2 h, 4: 71% from 3b, 66% from 3c. 2a,
3a: R = TBDMS; 2b, 3b: R = DMTr; 2c, 3c: R = Tr.
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compatibility of tricyclano synthesis with 4,4′-dimethoxytrityl
(DMTr), the standard protecting group in the solid phase
nucleic acid synthesis. Thus, the known compound 2b10 was
prepared and converted to the DMTr-protected uracil-tricy-
clano 3b in 76% yield over two steps (Scheme 2). The conden-
sation of the intermediate dialdehyde with E proceeded, again,
with the same diastereoselectivity as observed with the un-
protected and 5′-silyl protected dialdehydes, revealing that the
protecting group has no influence on the stereochemical
outcome of the cyclisation.
Removal of the DMTr group from 3b having an acid-sensi-
tive double aminal structure was a critical part of the reaction
path. Attempted experiments under standard conditions23
using dichloroacetic acid led to partial decomposition of the
tricycle of 3b. Hence, our attention was turned to find a new
method for DMTr cleavage which the acid sensitive tricyclano
could survive. For this purpose we have recently elaborated a
complex system of reagents including a Lewis acid (boron tri-
fluoride diethyl etherate), a reducing quenching agent (tri-
ethylsilane) and the mild protic acid, 1,1,1,3,3,3-hexafluoroiso-
propanol. This reagent cocktail, due to synergistic effect of the
components, proved to be efficient for rapid and clean de-
protection of a large variety of trityl- and dimethoxytrityl-
protected compounds.24 However, applying this method for
removal of the DMTr group of 3b, partial decomposition has
been observed. Since the Lewis acid is a variable component of
the reagent combination, by exchanging BF3·Et2O with the
milder Lewis acid zinc chloride, fine tuning of the reactivity
was achieved. Treating 3b with the reagent cocktail containing
zinc chloride the DMTr deprotection went to completion
within half an hour without noticeable decomposition, provid-
ing 4 in 71% yield.
The synthesis of the uracil-tricyclano was also carried
out using the cheap trityl (Tr) protecting group which
resulted in the corresponding tricyclano 3c with 76% overall
yield from 2c. To our delight, the ZnCl2-containing reagent
cocktail also cleaved the Tr protecting group of tricyclano 3c
without damaging the acid-sensitive tricyclic system
(Scheme 2). This result suggested that the O-DMTr protecting
group can be changed to the less expensive Tr group in our
further experiments.
The tricyclano derivative of ribothymidine was also pre-
pared using the Tr protecting group at position 5′ (Scheme 3).
First, 625 was synthesized and converted to 7 in two steps
including oxidation with metaperiodate followed by the con-
densation reaction with E. Finally, the trityl protecting group
was successfully cleaved by our detritylating reagent combi-
nation to result in 8 that was also prepared from unprotected
5. Acetylation of 8 furnished 9 which was used for structural
determination studies.
We envisioned that the synthesis of the cytosine-tricyclano
can be easily accomplished by using O,N-bistrityl protection.
Unexpectedly, simultaneous tritylation of the 5′ hydroxyl and
the amino group of 10 proved to be very sluggish and ineffi-
cient providing the bisprotected 11a in only 30% yield after a
ten-day reaction (Scheme 4). The usual oxidation and tricycli-
zation procedure showed similar efficacy as in the cases of
uridine and thymidine congeners to provide the cytosine-tri-
cyclano 13a in 65% isolated yield. Unfortunately, our new
detritylation method was not completely successful. Despite
the high excess of ZnCl2 (8 equiv.) only the O-Tr group could
be cleaved in a 5-hour reaction to give 14a in 56% yield.
Longer exposure of 13a to the detritylation conditions led
to decomposition of the tricyclic system rather than
N-deprotection. Therefore, we decided to change the N-trityl to
the more acid-sensitive N-DMTr protecting group. First, the
amino group of 10 was selectively protected with DMTr, then
the obtained 11b26 was selectively O-tritylated at the primary
position to result in 12b in 56% overall yield from 10. After
periodate oxidation, the resulting dialdehyde was reacted with
E to produce 13b in a good 72% yield over two steps. Finally,
13b was successfully treated with our detritylation cocktail to
result in 14b. Although TLC monitoring of the reaction
showed clean and efficient deprotection, 14b could only be iso-
lated in 26% yield because the purification process was
difficult due to the very poor solubility of the product.
Fig. 1 Numbering of tricyclano nucleosides having the 3,7,10-trioxa-
11-azatricyclo[5.3.1.05,11]undecane core.
Scheme 3 Synthesis of thymine-tricyclano 8 without protecting
groups and using the 5’-Tr protecting groups. Reagents and conditions:
(i) TrCl, dry C5H5N, rt, overnight, 75%; (ii) IO4
− resin, MeOH, rt, dark,
overnight; (iii) E, 3 Å MS, dry MeOH, rt, overnight, 7: 64% (2 steps from
6), 8: 53% (2 steps from 5); (iv) ZnCl2, (F3C)2CHOH, H3CNO2, Et3SiH, rt,
1 h, 8: 55% (from 7); (v) Ac2O, dry C5H5N, rt, overnight, 73%. 6, 7: R = Tr;
8: R’ = H; 9: R’ = Ac.
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To further explore the scope of the novel synthetic pathway
parallel to the synthesis of pyrimidine-based tricyclano,
similar experiments with inosine, adenosine, and guanosine
towards purine tricyclanos were also carried out. First, the
impact of the purine base on the cyclocondensation was
studied in the case of inosine (Scheme 5). The reaction
between Tris and the 5′-TBDMS- or Tr-protected dialdehyde
derivatives obtained from inosine via 16a27 or 16b28 afforded
17a or 17b, respectively, as the only products. Formation of
other stereoisomers was not visible, and the moderate yields
(52% for 17a and 42% for 17b over two steps) can be explained
mainly by the difficulty in purification of the tricyclic products
and, to a lesser extent, by the incomplete conversions of di-
aldehydes. The usual deprotection of both 17a and 17b yielded
efficiently the unprotected hypoxanthine-tricyclano 19, which
can also be obtained directly from 15 without protecting the 5′
position. 17b was acetylated to afford the crystalline 18b which
was recrystallized from i-PrOH. Fortunately, the obtained
crystal was good for X-ray diffraction and thereby gave us the
key for determination of the absolute configuration of the new
tricyclic ring system. The crystal structure of 18b is shown in
Fig. 2.
To get access to adenine-tricyclano, 20 was N-benzoylated
(21),29 silylated (22a)30 and subsequently transformed into 23a
(Scheme 6). The cyclocondensation led to the formation of a
single stereoisomer; however, partial loss of the benzoyl group
was observed, owing to the nucleophilicity of the Tris reactant.
The desilylation of 23a with TBAF and subsequent debenzoyl-
ation of the resulting 24a in methanolic ammonia took place
smoothly to provide the desired free tricyclano 25 in 86%
overall yield. In order to test the applicability of our new detri-
tylation method in a purine-containing tricyclano, the 6-N,5′-
O- bis tritylated adenosine derivative 22b31 was prepared. Next,
Scheme 4 Synthesis of cytosine-tricyclano using the O- and N-bis
trityl (including Tr and DMTr) protecting groups. Reagents and con-
ditions: (i) TrCl, DMAP, Et3N, dry DMF, 50 °C, 10 days, 11a: 30%; (ii)
TMSCl, DMTrCl, dry C5H5N, rt, 4 days, 11b: 82%; (iii) TrCl, dry C5H5N, rt,
7 days, 12b: 68%; (iv) IO4
− resin, MeOH : CH2Cl2 (13a: 3 : 1, 13b: 1 : 1), rt,
dark, 13a: overnight, 13b: 3 days; (v) E, 3 Å MS, dry MeOH, rt, 13a: 2 days,
13b: overnight, 13a: 65% (2 steps from 11a), 13b: 72% (2 steps from 12b);
(vi) ZnCl2, (F3C)2CHOH, H3CNO2, Et3SiH, rt, 5 h, 14a: 56% (from 13a), 7 h,
14b: 26% (from 13b); 11a, 13a: R = R’ = Tr, 11b: R = H, R’ = DMTr. 12b,
13b: R = Tr, R’ = DMTr; 14a: R = H, R’ = Tr; 14b: R = R’ = H.
Scheme 5 Synthesis of hypoxanthine-tricyclano 19 via unprotected,
TBDMS- and Tr-protected dialdehyde intermediates. Reagents and con-
ditions: (i) TBDMSCl, imidazole, dry DMF, rt, overnight, 16a: 54%; (ii) TrCl,
dry C5H5N, dry DMF, dry DMSO, 60 °C, 4 days, 16b: 39%; (iii) IO4
− resin,
MeOH, rt, dark, overnight; (iv) E, 3 Å MS, dry MeOH, rt, overnight, 19:
38% (2 steps from 15), 17a: 52% (2 steps from 16a), 17b: 42% (2 steps
from 16b); (v) Ac2O, dry C5H5N, rt, overnight, 18b: 86% (from 17b); (vi)
TBAF, dry THF, rt, overnight, 19: 56% (from 17a); (vii) ZnCl2, (F3C)2CHOH,
H3CNO2, Et3SiH, rt, 2 h, 19: 58% (from 17b). 16a: R = TBDMS; 16b: R =
Tr; 17a: R = TBDMS, R’ = H; 17b: R = Tr, R’ = H; 18b: R = Tr, R’ = Ac.
Fig. 2 ORTEP view of the structure of compound 18b, at 40% prob-
ability level with a partial numbering scheme. One of the molecules
from the asymmetric unit is shown and the solvent molecules are
omitted for clarity.
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22b was converted to 23b using the usual two-step reaction
including oxidation followed by cyclocondensation of the
obtained dialdehyde with Tris. The complete deprotection of
23b required an overnight treatment with the detritylating
cocktail containing 8 equiv. of ZnCl2. Fortunately, despite the
long reaction time and high excess of Lewis acid, neither
depurination nor decomposition of the tricyclic core occurred
in a noticeable amount and compound 25 was isolated in 63%
yield.
Finally, in order to extend our synthetic method to all ribo-
nucleosides, guanine-tricyclano 29 was also prepared
(Scheme 7). First, guanosine 26 was selectively tritylated at the
primary hydroxyl and the amino group of the heterocyclic base
to obtain 27a,32 which was transformed into the tricyclano 28a
in high efficacy (73% yield) by the usual two-step procedure.
Unexpectedly, complete deprotection required a three-day reac-
tion with the detritylating cocktail, upon which decomposition
also occurred, and the desired product could not be isolated.
To avoid decomposition upon deprotection, the above syn-
thetic route from 26 to 28 was carried out by the use of the
more acid-labile DMTr protecting group. For this purpose, 26
was treated with TMSCl and DMTrCl to produce the required
O- and N-bis(dimethoxytrityl) derivative 27b33 in 47% yield,
together with the mono-N-protected by-product 27c.
Transformation of 27b into the tricyclano derivative was
carried out in the usual manner to obtain 28 in 80% yield. To
our great delight, treatment of 28b with our mild reagent com-
bination led to a satisfactory level of O-and N-deprotection
within 5 hours and the required fully deprotected guanosine
derivative 29, the last member of the tricyclano family, could
successfully be isolated and characterised. We assume that the
moderate yield of 29, which was mainly caused by incomplete
deprotection, can be increased by further fine tuning of the
detritylation conditions.
Determination of the absolute configuration
Simple NMR methods (e.g. 3JHH coupling constants) were
insufficient to unambiguously disclose the stereochemistry
around the three new stereocenters which might be due to the
conformational diversity predicted theoretically (see Fig. S4 in
the ESI†). Finally, the combined use of X-ray crystallography, a
new NMR ROESY method for H–H distance determination and
chemical shift calculations based on theoretical conformation-
al distribution and comparison with NMR data gave satisfac-
tory results.
X-ray studies
X-ray quality crystals of 18b were grown from i-propanol.
Details of data collection and summary of parameters are
given in the ESI, Table S1.† In the structure, hydrogen atoms
were placed into geometric positions except for the N–H and
O–H protons which could be located in the difference electron
density maps but the N–H and O–H distances were restrained.
The O–H hydrogen atoms of the solvent i-propanol were shift-
ing between two orientations and the small disorder of the
solvent molecule was not modelled as chemical evidence indi-
cated the presence of i-propanol molecules. However this did
not affect the overall correctness of the structure determi-
nation. The isotropic displacement parameters of the hydro-
gen atoms were approximated from the U(eq) value of the
Scheme 7 Synthesis of guanine-tricyclano 29 with O- and N-bis trityl
and the O- and N-bis(dimethoxytrityl) protecting groups. Reagents and
conditions: (i) TrCl, DMAP, Et3N, dry DMF, 50 °C, 10 days, 27a: 49%; (ii)
TMSCl, DMTrCl, dry DMF, dry C5H5N, 4 days, 27b: 47%, 27c: 30%; (iii)
NaIO4, MeOH : H2O (3 : 1) or IO4
− resin, MeOH : CH2Cl2 (2 : 3), rt, dark,
overnight; (iv) E, 3 Å MS, dry MeOH, rt, 28a: 2 days, 28b: overnight, 28a:
73% (2 steps from 27a), 28b: 80% (2 steps from 27b); (v) ZnCl2,
(F3C)2CHOH, H3CNO2, Et3SiH, rt, 5 h, 20% (from 28b). 27a, 28a: R = R’ =
Tr; 27b, 28b: R = R’ = DMTr; 27c: R = H, R’ = DMTr; 29: R = R’ = H.
Scheme 6 Synthesis of adenine-tricyclano 25 using O-TBDMS and
N-benzoyl or the O- and N-bis trityl protecting group. Reagents and
conditions: (i) TMSCl, Bz2O, dry C5H5N, rt, overnight, then H2O, cc. NH3,
21: 96%; (ii) TBDMSCl, DMAP, 4 Å MS, dry C5H5N, rt, overnight, 22a: 83%
(from 21); (iii) TrCl, dry C5H5N, 60 °C, overnight, 22b: 63% (from 20); (iv)
IO4
− resin, MeOH, rt, dark, overnight; (v) E, 3 Å MS, dry MeOH, rt, over-
night, 23a: 24% (2 steps from 22a), 23b: 70% (2 steps from 22b); (vi) IO4
−
resin, MeOH : CH2Cl2 (3 : 2), rt, dark, overnight; (vii) TBAF, dry THF, rt,
overnight, 24a: 92% (from 23a); (viii) cc. NH3, MeOH, rt, overnight, 25:
95% (from 24a); (ix) ZnCl2, (F3C)2CHOH, H3CNO2, Et3SiH, rt, 24 h, 63%
(from 23b); 20: R = H; 21: R = Bz; 22a, 23a: R = Bz, R’ = TBDMS; 22b,
23b: R = R’ = Tr; 24a: R = Bz, R’ = H.
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atom they were bonded to. Refinement of the non-hydrogen
atoms was carried out with anisotropic temperature factors. The
selected bond lengths and angles of compound 18b are shown
at Tables S2 and S3,† respectively. The space group was non-
centrosymmetric and the results unambiguously support that
the sample is enantiopure. The high sensitivity of the detector
made it possible to determine the absolute configuration
reliably on the basis of the anomalous dispersion effect. The
Flack parameter for 4034 quotients was found to be 0.03(12).34
The absolute configuration for both 18b molecules is
(1R,2S,5R,8R,9R). The structure is stabilized by weak C–H⋯O
and C–H⋯N hydrogen bonds. There are also hydrogen bonds
between the i-propanol molecules and O–H bond of one of the
i-propanol molecules and carbonyl oxygen of the hypoxanthine
moiety (O96). Altogether bond length and bond distance data
correspond to the expected values35 and distance of N11 from
the C2–C5–C8 plane is 0.497 and 0.515 Å for the two mole-
cules, respectively. Ring puckering analysis36 of the structure
revealed that the 5-membered rings of N11–C2–O3–C4–C5 and
N11–C8–O7–C6–C5 have envelope conformation on O3 and
O7, respectively (Fig. S165†). However, the six membered ring
of N11–C2–C1–O10–C9–C8 is very strained as the C1–C2–N11–
C8 atoms are in one plane (Fig. S166†) while C9 and O10 are at
the same side of the plane resembling a half chair confor-
mation. The C1–C2 and C51–C52 distances are both 1.516(7) Å
indicating sp3 carbons. The angle of C1–O10 and C1–C2–N11–
C8 planes is 58 degrees (52 degrees for the other molecule in the
asymmetric unit). A search of the Cambridge Structural
Database (Ver. 5.38, update May, 2017)37 resulted in around
2600 hits for the morpholine ring moiety in organic com-
pounds. The histogram for the angle of the said planes is
shown in Fig. S165† clearly demonstrating that our system
with a 52–58 degree angle is rather unique.
DFT NMR calculations
For the DFT NMR studies all possible 8 : 8 stereoisomers of 3c
and 9, the proven one of 18b and the presumed one of 13a
were utilized. For each stereoisomer an OPLS (Optimized
Potentials for Liquid Simulations)38 conformational search
was carried out for CHCl3 and conformers were saved in a
21 kJ mol−1 energy window. These conformers were reopti-
mized at the B3LYP/6-31+G(d,p) level and NMR shift values
were computed for conformers over 1% Boltzmann population
at the mPW1PW91/6-311+G(2d,p) level.39 Corrected C and
H-NMR data40 were compared to the experimental shift values.
While for 9 the C-NMR data (Table S7†) alone were rather per-
suasive, for 3c a combination of C (Table S5†) and H-NMR
data (Table S6†) was necessary to distinguish between the 8
stereoisomers resulting in the same diastereomer elucidated
by X-ray crystallography for 18b. Corrected mean absolute
error (CMAE) values41 and largest deviations from the experi-
mental data of 18b and 13a were similar for the single investi-
gated stereoisomers as for the best stereoisomers of 3c and 9
(Tables S9–S12†). Therefore, from the computational NMR
results for all tricyclanos the products are homochiral with the
X-ray-determined compound 18b.
Newly developed distance-based experimental NMR method to
elucidate stereochemistry
A recently introduced zero-quantum suppressed off-resonance
ROESY method42 (an easy-ROESY variant) proved to be
especially useful to corroborate stereochemical conclusions.
Since the method is less sensitive to zero-quantum artifacts
present between scalar-coupled nuclei (e.g. the CH2 groups or
the aromatic ortho protons used for distance calibration), good
distance agreement was found between NMR and X-ray tech-
niques (Fig. S167–S169 and Table S4†) where an independent
X-ray structure was available (18b). Interestingly, theoretical
calculations showed conformational diversity of the tricyclic
ring and the side chains that prevents the possibility of direct
comparison with ad hoc selected conformers. Conformational
diversity was recently shown to persist in “rigid” molecules
like strychnine.43 For the 500 MHz off-resonance ROESY
spectra, typically a magic tilt angle of theta = 54.7° was used,
with a spin lock field strength of 8.33 kHz (p90 = 30 us) at ±5.9
kHz offsets applied in the two halves of the mixing time of
200 ms. For zero quantum filtering adiabatic chirp pulses of
30 and 50 ms with simultaneous spoil gradients were used as
described in ref. 42.
Mechanism
We suppose that the formation of the new tricycle can be
described as a series of consecutive reactions (Scheme 8). First
a Schiff base (i2) is formed through a hemiaminal (i1) followed
by an intramolecular addition of one of the primary alcohols
resulting in the oxazolidine i3. A second hemiaminal (i4) is
formed by the addition of the NH group to the second alde-
hyde. The final step is the addition of the second hydroxyl
group onto the iminium intermediate i5. The stereoselectivity
of the reaction is controlled by the two chiral centers of the
dialdehyde. Since the water side product is continuously
removed with molecular sieves there is no equilibration in the
particular reaction steps. Therefore, we postulate that for-
mation of the kinetic product is preferred resulting in the high
stereoselectivity of the reaction. The observed stereochemistry
at C2 and C8 is in accordance with the polar Felkin–Anh
model generally applied for the addition reactions of alde-
Scheme 8 Proposed mechanism of the imine-oxazolidine and
iminium-oxazolidine cascade reactions. (The first attack of the amine on
one of the two aldehyde moieties is interchangeable.)
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hydes or ketones with an electronegative group.44 Chiral
centers at C2 and C5 (or at C8 and C5) form simultaneously in
the final cyclisation step.
Conclusions
In conclusion, we developed a new type of nucleoside analogue
by the stereoselective transformation of the ribose unit
of nucleosides to a novel, specific heterotricyclic system com-
prising a morpholine ring and two 1,3-oxazolidine rings. The
implemented synthesis is very simple including an oxidation
step followed by a cyclocondensation of the resulting
dialdehyde with the commercially available and cheap
reagent Tris. The highly efficient and stereoselective formation
of one isomeric form of the newly generated stereotriade
observed in the condensation reactions can be explained by
the induced fitting of the reactants. The reaction proceeds
through two consecutive hemiaminal–oxazolidine cascade
reactions and the stereoselectivity is governed by the two
stereogenic centers of the nucleoside-derived dialdehydes. The
stereochemistry was unambiguously proved by single crystal
X-ray diffraction for 18b in agreement with NMR ROESY and
computational methods that allowed assigning absolute con-
figuration in the absence of X-ray structures. A combined
approach was necessary because of the theoretically predicted
flexibility of the tricycle. The synthetic method is compatible
with both purine and pyrimidine bases as well as bulky pro-
tecting groups like TBDMS, Tr or DMTr. Using a ZnCl2-Et3SiH-
(F3C)2CHOH-containing reagent system, due to the beneficial
synergism of the components, the Tr and DMTr protecting
groups of tricyclanos could efficiently be cleaved in most cases
– except for the N-trityl group of cytosine and guanine – and
this mild deprotection method neither affected the acid-sensi-
tive double aminal system nor caused depurination.
Studies towards the synthesis of tricyclano-containing oligo-
nucleotide derivatives and utilisation of the tricyclisation
method for producing new N-containing heterotricyclic
systems are under way.
Experimental
Typical procedure for the cyclocondensation reaction between the
nucleoside dialdehyde and Tris: 12′-O-trityl-uracil-tricyclano (3c)
To a solution of 2c (2.00 g, 4.13 mmol) in MeOH (100 mL) the
IO4
−-form of anion exchange resin (8.0 g) was added and
stirred overnight in the dark. The next day the resin was filtered
off through a short pad of Celite® and washed successively
with MeOH and CH2Cl2. The solvent was evaporated in
vacuum. The residue was dissolved in dry MeOH (100 mL) and 3 Å
molecular sieves (2 g) were added to the reaction. After stirring
for half an hour, Tris (747 mg, 6.17 mmol, 1.5 equiv.) was
added to the mixture. The next day another portion of Tris
(249 mg, 2.06 mmol, 0.5 equiv.) was added to the stirred reac-
tion mixture. After a total reaction time of 2 days the molecular
sieves were filtered off through a short pad of Celite® and
washed successively with MeOH and CH2Cl2. The solvent was
evaporated under vacuum and the crude product was purified by
flash column chromatography (CH2Cl2/MeOH 98 : 2 → 98 : 3 →
97 : 3) to yield compound 3c (1.78 g, 76%, over two steps) as
a white foam. Rf = 0.42 (CH2Cl2/MeOH 95 : 5);
1H NMR
(400 MHz, CDCl3) δ = 9.77 (s, 1H, NH), 7.48 (d, J = 8.2 Hz, 1H,
uracil CH-6), 7.43 (d, J = 7.3 Hz, 6H, 6 × Tr Ar–H), 7.29 (t, J =
7.4 Hz, 6H, 6 × Tr Ar–H), 7.23 (t, J = 7.2 Hz, 3H, 3 × Tr Ar–H),
6.14 (d, J = 4.7 Hz, 1H, H-1′), 5.67 (d, J = 8.2 Hz, 1H, uracil CH-
5), 4.80 (d, J = 4.6 Hz, 1H, H-8′), 4.68 (d, J = 4.7 Hz, 1H, H-2′),
4.21 (q, J = 4.4 Hz, 1H, H-9′), 3.87 (d, J = 9.0 Hz, 2H, H-6′a, H-4′
a), 3.78 (d, J = 8.9 Hz, 1H, H-6′b), 3.77 (d, J = 8.8 Hz, 1H, H-4′
b), 3.64 (d, J = 5.5 Hz, 2H, H-13′a,b), 3.38 (d, J = 4.3 Hz, 2H,
H-12′a,b), 2.90 (t, J = 5.8 Hz, 1H, OH); 13C NMR (100 MHz,
CDCl3) δ = 163.4 (1C, uracil CO-4), 150.5 (1C, uracil CO-2),
143.5 (3C, 3 × Tr Ar–C), 139.9 (1C, uracil CH-6), 128.7, 128.0,
127.3 (15C, 15 × Tr Ar-CH), 103.0 (1C, uracil CH-5), 90.3 (1C,
C-2′), 88.4 (1C, C-8′), 87.1 (1C, Tr Cq), 77.7 (1C, C-1′), 75.3 (1C,
C-5′), 73.9 (1C, C-9′), 72.0 (1C, C-4′), 71.3 (1C, C-6′), 63.7 (1C,
C-13′), 63.6 (1C, C-12′); ESI-TOF-MS: m/z calcd for
C32H31N3NaO7 [M + Na]
+ 592.206, found 592.205.
Typical deprotection procedure using the three-component
detritylating cocktail: uracil-tricyclano (4)
3c (342 mg, 0.60 mmol) was added to the mixture of ZnCl2
(342 mg, 2.51 mmol, 4.2 equiv.), hexafluoroisopropanol
(6 mL), MeNO2 (3 mL) and Et3SiH (600 μL, 3.76 mmol, 6.3
equiv.). After 2 hours a saturated NaHCO3-solution was added
and the solvents were evaporated. The crude product was puri-
fied by flash column chromatography (CH2Cl2/MeOH 9 : 1 →
8 : 1 → 85 : 15 → 8 : 2) to yield 4 (129 mg, 66%) as a white
foam. Rf = 0.45 (CH2Cl2/MeOH 85 : 15);
1H NMR (400 MHz,
D2O + CD3OD) δ = 7.78 (d, J = 8.1 Hz, 1H, uracil CH-6), 6.04 (d,
J = 5.0 Hz, 1H, H-1′), 5.88 (d, J = 8.1 Hz, 1H, uracil CH-5), 4.77
(d, J = 5.1 Hz, 1H, H-2′), 4.70 (d, J = 4.1 Hz, 1H, H-8′), 4.15 (dd,
J = 3.9, 1.3 Hz, 1H, H-9′), 4.00 (d, J = 9.1 Hz, 1H, H-6′a),
3.93–3.86 (m, 2H, H-4′a,b), 3.85–3.71 (m, 3H, H-6′b, H-12′a,b),
3.69 (s, 2H, H-13′a,b); 13C NMR (100 MHz, D2O + CD3OD) δ =
166.6 (1C, uracil CO-4), 152.3 (1C, uracil CO-2), 142.6 (1C,
uracil CH-6), 103.8 (1C, uracil CH-5), 90.8 (1C, C-2′), 89.1 (1C,
C-8′), 79.1 (1C, C-1′), 75.9 (1C, C-9′), 75.6 (1C, C-5′), 73.0 (1C,
C-4′), 72.2 (1C, C-6′), 63.6 (1C, C-13′), 62.7 (1C, C-12′);
ESI-TOF-MS: m/z calcd for C13H17N3NaO7 [M + Na]
+ 350.096,
found 350.093.
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